Johnson & Johnson To Separate Orthopedics Business, Boosts Annual Sales Outlook
1. JNJ reported Q3 2025 adjusted earnings of $2.80, beating estimates. 2. Sales increased 6.8% YoY to $23.99 billion, above consensus. 3. Orthopedics business separation may enhance strategic focus and margins. 4. Cancer therapy sales rose 21.3%, while immunology sales declined. 5. Company in talks to acquire Protagonist Therapeutics for new treatments.